Onco-Innovations Advances PNKP Inhibitor ONC010 Toward First-in-Human Studies

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response (DDR) therapy market that is distinct from established PARP inhibitor therapies.

Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph causal AI platform to support patient stratification, clinical trial design and oncology evidence generation. Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies.

Onco-Innovations is a clinical-stage oncology company focused on advancing a new class of DDR therapies and developing artificial intelligence-driven precision oncology solutions. The company is leading the development of Polynucleotide Kinase Phosphatase inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance. Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.

The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions and research partnerships. For the latest news and updates relating to ONNVF, visit the company’s newsroom at https://ibn.fm/ONNVF.

InvestorWire is a specialized communications platform with a focus on advanced wire-grade press release syndication. It is one of 75+ brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. For more information, visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW at https://www.InvestorWire.com/Disclaimer.